Biomarker Tests: Delaware’s New Play for Cancer Care

Delaware faces a new challenge in the fight against cancer, one that could change how patients are treated. The state’s lawmakers are considering a bill that would require health plans, including Medicaid, to cover comprehensive biomarker testing. This test looks at a patient’s cells for clues that can guide doctors toward the most effective treatments. The idea is simple: by knowing more about a tumor’s unique features, doctors can choose therapies that are more likely to work and avoid those that would only cause side‑effects. Research shows that patients who receive biomarker‑guided care have better chances of surviving, even when dealing with tough cancers like lung or breast cancer. Beyond oncology, biomarker tests are useful for other conditions such as arthritis, autoimmune disorders, and organ transplants. In fact, many new medicines emerging from clinical trials rely on these tests to identify the right patients.Right now, about a quarter of Delaware residents are stuck with insurance plans that do not cover these essential tests. That means many people who could benefit from targeted treatments are left out of the loop. The gap is not random; it often falls along lines of race, age, and income. Studies have shown that Black patients or those on Medicaid are less likely to get the latest testing than their white, commercially insured counterparts. If Delaware does not act, these disparities will grow. By adding biomarker coverage to state insurance plans, the state could join 23 others that already offer better access. This would not only improve outcomes for cancer patients but also open doors to cutting‑edge clinical trials and reduce health inequities across the board. The bill has support from Governor Meyer, who highlighted its importance in his budget speech. Senators and representatives are pushing the legislation forward, hoping to give Delawareans a fair shot at precision medicine.